Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

16.03.22	Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease (GlobeNewswire)
16.03.22	Biogen: ADUHELM Continues To Reduce Underlying Pathologies Of Alzheimer's Beyond Two Years (RTTNews)
16.03.22	Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years (GlobeNewswire)
15.03.22	Biogen, Eisai Amend Collaboration Agreement On Alzheimer's Disease Treatments (RTTNews)
15.03.22	Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments (GlobeNewswire)
14.03.22	Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference (GlobeNewswire)
11.03.22	Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022) (GlobeNewswire)
07.03.22	Statement of acquisition of beneficial ownership by individuals (RSS)
05.03.22	Charles Schwab To Replace Biogen In S&P 100 (RTTNews)
05.03.22	Charles Schwab Set to Join S&P 100; BellRing Brands to Join S&P MidCap 400; Cerence to Join S&P SmallCap 600 (PR Newswire)
04.03.22	Biogen Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Biogen, Inc. (NASDAQ: BIIB); Lead Plaintiff Deadline is April 8, 2022 (PR Newswire)
04.03.22	EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL AN... (PR Newswire)
23.02.22	Form 4 875045 (RSS)
16.02.22	Sage : Phase 3 Study Of Zuranolone On Major Depressive Disorder Meets Primary & Secondary Endpoints (RTTNews)
15.02.22	Form 4 875045 (RSS)
08.02.22	Biogen Reaches Deal With Xbrane For Proposed Biosimilar To Cimzia (RTTNews)
07.02.22	Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis (GlobeNewswire)
03.02.22	Biogen Posts Adj. Profit In Q4; Sees FY22 Results Below Market (RTTNews)
01.02.22	Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody (GlobeNewswire)
31.01.22	Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors (GlobeNewswire)
31.01.22	Form 8-K 875045 (RSS)
28.01.22	Samsung Biologics To Buy Biogen's Stake In Samsung Bioepis JV For Up To $2.3 Bln (RTTNews)
28.01.22	Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion (GlobeNewswire)
27.01.22	Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM® (GlobeNewswire)
21.01.22	Form 4 875045 (RSS)
12.01.22	Pre-market Movers: IMRN, PIK, NTP, FLUX, MCMJ… (RTTNews)
04.01.22	Biogen Licenses Global Rights To Develop, Commercialize SPINRAZA From Ionis Pharma (RTTNews)
04.01.22	Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA (GlobeNewswire)
04.01.22	Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA (PR Newswire)
30.12.21	Biogen/Samsung Takeover - Deal Or No Deal? (RTTNews)
24.12.21	INVESTIGATIONAL ALZHEIMER'S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK DESIGNATION (PR Newswire)
22.12.21	Biogen: Japan's NDC Seeks Additional Data On Application For Approval Of Aducanumab (RTTNews)
22.12.21	Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review (GlobeNewswire)
20.12.21	Biogen Cuts Price For ADUHELM To Improve Patient Access; To Implement Cost-reduction Measures (RTTNews)
20.12.21	Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease (GlobeNewswire)
17.12.21	Biogen To Seek Re-examination Of Negative Opinion By EMA For Its 'aducanumab' (RTTNews)
17.12.21	Update on Regulatory Submission for Aducanumab in the European Union (GlobeNewswire)
16.12.21	Update on the Phase 4 Confirmatory Study of ADUHELM® (GlobeNewswire)
14.12.21	Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience (GlobeNewswire)
08.12.21	Sage Announces Presentation Of Analyses From Clinical Program Of Zuranolone In MDD (RTTNews)
06.12.21	Form 4 875045 (RSS)
01.12.21	Sage Announces Positive, One-Year Zuranolone 50 Mg Data On Major Depressive Disorder (RTTNews)
01.12.21	Viatris Wins Federal Circuit Court Appeal On Biogen's Tecfidera Patent - Quick Facts (RTTNews)
17.11.21	EU Panel Recommends Negative Trend Vote On Biogen's Alzheimer Drug (RTTNews)
17.11.21	Update on Regulatory Review of Aducanumab in the European Union (GlobeNewswire)
16.11.21	The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis (GlobeNewswire)
16.11.21	Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development (GlobeNewswire)
15.11.21	Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year (GlobeNewswire)
11.11.21	New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease (GlobeNewswire)
11.11.21	Introduction of First-Of-A-Kind Plasma-Based Biomarker Screening To Facilitate Identification Of Subjects For Phase 3 Ahead 3-45 Trial Presented At Clinical Trials On Alzheimer's Disease (CTAD) Co... (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

20:04		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
17:58		Zurückhaltung in Frankfurt: SDAX beendet die Dienstagssitzung mit Verlusten
17:58		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer
17:58		Schwacher Handel in Frankfurt: TecDAX schwächelt zum Handelsende
15:58		Schwacher Handel: SDAX fällt nachmittags
15:58		Minuszeichen in Frankfurt: TecDAX verbucht nachmittags Verluste
15:17		Bayer expandiert: Japan-Lizenz für potenzielles Herzmedikamentenkandidaten gesichert - Aktie tiefer
12:26		Dienstagshandel in Frankfurt: TecDAX präsentiert sich mittags leichter

20:04

Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein

17:58

Zurückhaltung in Frankfurt: SDAX beendet die Dienstagssitzung mit Verlusten

17:58

Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer

17:58

Schwacher Handel in Frankfurt: TecDAX schwächelt zum Handelsende

15:58

Schwacher Handel: SDAX fällt nachmittags

15:58

Minuszeichen in Frankfurt: TecDAX verbucht nachmittags Verluste

15:17

Bayer expandiert: Japan-Lizenz für potenzielles Herzmedikamentenkandidaten gesichert - Aktie tiefer

12:26

Dienstagshandel in Frankfurt: TecDAX präsentiert sich mittags leichter

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Biogen Inc

Aktien Top/Flop

Biogen Peer Group Nachrichten

Meistgelesene Nachrichten